[Transitional psychiatry in Flanders: a proactive strategy]. / Transitiepsychiatrie in Vlaanderen; een proactieve strategie.

background Psychiatric disorders in adults often result from psychiatric problems during childhood and adolescence. aim In the light of prevention of psychiatric disorders in adults, we focus on adolescence. method Based on the working method of the transitional psychiatry unit, we describe the characteristics of the patient group and the necessities of adequate treatment and care for young people who are suffering from a stagnation in development due to psychiatric problems. results Family therapy, new authority/non-violent resistance and our own RAISING skills are tools for treating these young people. Here we focus on the adolescent's development. This early treatment prevents the development of irreversible symptoms and serious psychiatric illness during adulthood. conclusion Transitional psychiatry forms part of the answer in the search of pro-active medicine. Tijdschrift voor Psychiatrie 63(2021)2, 115-119.

[Effectiveness of guanfacin on comorbid disorders in children and adolescents with adhd: a systematic literature review]. / Effectiviteit van guanfacine bij comorbide stoornissen bij kinderen en jongeren met ADHD: systematische literatuurstudie.

BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is a frequently occurring problem in child and adolescent psychiatry. Most prevalent comorbid disorders are oppositional defiant behavior, tics, autism spectrum disorder, anxiety and depression. Stimulants are the first pharmacological choice. Recently, long-acting guanfacin became available in Belgium and the Netherlands.
AIM: To investigate the efficacy of guanfacin on comorbid symptoms in ADHD.
METHOD: A systematic search in Medline and Cochrane databases for randomized controlled trials in which the effect of guanfacin on comorbid symptoms is evaluated.
RESULTS: Guanfacin had an effect on autism symptoms, oppositional defiant symptoms and possibly on tics in children and adolescents with adhd. On anxiety symptoms, no effect was reported. The effect on depression needs to be further investigated. The side effects of guanfacin are similar in comorbid disorders and pure ADHD.
CONCLUSION: Guanfacin is a treatment option for ADHD in children and adolescents with comorbid autism or behavioural symptoms and possibly also tics, as it has a demonstrated effect on these comorbid features. Further research is necessary in order to decide on the preference for a particular medication in ADHD with these various comorbid disorders.